#1 Clinical Trials Search in Europe

Lasn01

LASN01 is a novel, fully human antibody being investigated as a potential treatment for Thyroid Eye Disease (TED). This article explores the ongoing clinical trials evaluating the safety, efficacy, and pharmacokinetics of LASN01 in patients with TED, including those who have not received prior anti-IGF-1R treatment and those who have previously been treated with teprotumumab.

Table of Contents

What is LASN01?

LASN01 is a new medication currently being studied for its potential to treat certain eye and lung conditions. It is described as a novel, fully human antibody that targets a specific receptor in the body called the human IL-11 receptor[1]. An antibody is a protein produced by the immune system to fight off harmful substances. In this case, scientists have created an antibody that can potentially help treat certain diseases.

What Conditions Does LASN01 Treat?

LASN01 is being developed to treat two main conditions:

  1. Thyroid Eye Disease (TED): Also known as Graves’ ophthalmopathy, Graves’ orbitopathy, or thyroid-associated ophthalmopathy. This is an eye condition related to thyroid problems that can cause bulging eyes, double vision, and other eye-related symptoms[1].
  2. Pulmonary Fibrosis: A lung disease that causes scarring (fibrosis) of the lungs, making it difficult to breathe. The study specifically mentions two types:
    • Idiopathic Pulmonary Fibrosis (IPF)
    • Progressive Fibrosing Interstitial Lung Disease (PF-ILD)[2]

How Does LASN01 Work?

LASN01 works by targeting the IL-11 receptor in the body. While the exact mechanism isn’t fully explained in the provided information, it’s mentioned that LASN01 is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and thyroid eye disease[2]. This suggests that LASN01 may help reduce inflammation and prevent the formation of excess fibrous tissue, which are common problems in both conditions.

Current Clinical Trials

LASN01 is currently being studied in clinical trials to determine its safety and effectiveness. Two main studies are described:

  1. A Phase 2 study specifically for Thyroid Eye Disease patients[1].
  2. A Phase 1/2a study that includes healthy volunteers and patients with pulmonary fibrosis or thyroid eye disease[2].

These trials are designed to test different doses of LASN01 and compare it to a placebo (a substance with no active medication) to see how well it works and if it’s safe to use.

How is LASN01 Administered?

According to the clinical trial information, LASN01 is administered intravenously (IV), which means it’s given directly into a vein[1][2]. The studies are testing different doses and schedules of administration to find the most effective and safe approach.

Effectiveness of LASN01

As LASN01 is still in clinical trials, its full effectiveness is not yet known. However, the studies are measuring several outcomes to determine how well it works, including:

  • For Thyroid Eye Disease:
    • Changes in proptosis (eye bulging)[1]
    • Changes in Clinical Activity Score (CAS), which measures eye inflammation[1]
    • Changes in lid aperture, lid retraction, and eye movements[1]
    • Improvements in double vision[1]
  • For Pulmonary Fibrosis:
    • The trial information doesn’t specify particular effectiveness measures for pulmonary fibrosis, but it’s likely that lung function tests and other respiratory assessments will be used[2]

Safety and Side Effects

As with any new medication, understanding the safety profile and potential side effects of LASN01 is a crucial part of the clinical trials. The studies are closely monitoring:

  • Treatment-emergent and treatment-related adverse events[2]
  • Serious adverse events[2]
  • Changes in laboratory test results[2]
  • Changes in vital signs, electrocardiogram (ECG) results, and physical examination findings[2]

It’s important to note that as LASN01 is still in clinical trials, it is not yet approved for general use. Patients interested in this treatment should speak with their healthcare providers about the possibility of participating in clinical trials or waiting for further research results.

Aspect Details
Drug Name LASN01
Type Novel, fully human antibody targeting IL-11 receptor
Condition Treated Thyroid Eye Disease (TED)
Administration Intravenous (IV)
Study Design Randomized, double-masked, placebo-controlled
Patient Groups TED patients without prior anti-IGF-1R treatment, TED patients previously treated with teprotumumab
Primary Outcomes Changes in proptosis, adverse events
Secondary Outcomes Changes in Clinical Activity Score, lid aperture, lid retraction, lagophthalmos, Von Graefe’s sign, extraocular movements, diplopia
Study Phases Phase 1/2a and Phase 2

FAQ

  • What is LASN01? LASN01 is a new, fully human antibody that targets the human IL-11 receptor. It is being developed as a potential treatment for Thyroid Eye Disease (TED), which is a condition affecting the eyes and surrounding tissues.
  • How is LASN01 administered in clinical trials? In the clinical trials, LASN01 is administered intravenously (through a vein) to patients. The trials are testing different doses of the drug, including low and high doses.
  • What are the main goals of the LASN01 clinical trials? The main goals of the clinical trials are to evaluate the safety, efficacy, and how the body processes LASN01 (pharmacokinetics) in patients with Thyroid Eye Disease. The studies are also looking at how well the drug works in patients who have not received previous treatments and those who have been treated with another drug called teprotumumab.
  • What are some of the outcomes being measured in these trials? The trials are measuring several outcomes, including changes in proptosis (bulging of the eyes), Clinical Activity Score (CAS), lid aperture, lid retraction, eye movements, and double vision. They are also closely monitoring any side effects or adverse events that patients may experience.
  • Who can participate in these LASN01 clinical trials? The trials include patients with Thyroid Eye Disease. Some parts of the studies involve patients who have not received prior anti-IGF-1R treatment, while other parts include patients who have previously been treated with teprotumumab. There are also parts of the study that involved healthy volunteers to assess the initial safety of the drug.

Ongoing Clinical Trials on Lasn01

  • Study on the Safety and Effectiveness of LASN01 for Patients with Thyroid Eye Disease

    Not recruiting

    1 1
    Investigated drugs:
    Germany Spain

Glossary

  • Thyroid Eye Disease (TED): A condition where the eye muscles, eyelids, tear glands and fatty tissues behind the eye become inflamed. This can cause the eyes to bulge outwards and can affect vision.
  • Proptosis: The forward displacement or bulging of the eye, often seen in Thyroid Eye Disease.
  • Clinical Activity Score (CAS): A standardized method used to assess the activity and severity of Thyroid Eye Disease.
  • Exophthalmometer: A device used to measure the degree of protrusion of the eye.
  • Intravenous (IV): A method of administering medication directly into a vein.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Double-masked: A study design where neither the participants nor the researchers know who is receiving the actual treatment and who is receiving a placebo.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Lagophthalmos: The inability to close the eyelids completely.
  • Von Graefe's sign: A medical sign where the upper eyelid lags behind when the eye looks downward, often seen in Thyroid Eye Disease.
  • Diplopia: Double vision, where a single object appears as two objects.
  • Bahn-Gorman Scale: A scale used to assess the severity of double vision in patients with Thyroid Eye Disease.

References